Table 3 Summary of clinical results from the GOG 132 study of 3-weekly paclitaxel 135 mg m−2 over 24 h plus cisplatin 75 mg m−2 compared with cisplatin alone (100 mg m−2) or paclitaxel alone (200 mg m−2 over 24 h), each for six cycles (Muggia et al, 2000)

From: Primary ovarian cancer chemotherapy: current standards of care

Treatment arm No. of patients evaluable for clinical response Overall response rate (%) Complete response rate (%) Median progression-free survival (months) Median overall survival (months)
Cisplatin 122 67* 42 16.4* 30.2
Paclitaxel 131 42* 21 10.8* 25.9
Cisplatin+paclitaxel 124 67* 43 14.1* 26.3
  1. Statistically significant difference between treatments (P<0.05).